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Abstract 
Energy depletion caused by ischemic brain insults may result in persistent neuronal depolarization 
accompanied by hyper-stimulation of ionotropic glutamate receptors and excitotoxic phenomena, 
possibly leading to cell death. Thus, the use of glutamate receptor antagonists, such as the AMPARs 
antagonist Perampanel (PER), might be a pharmacological approach to counteract the excessive 
over-activation of glutamate receptors providing neuroprotective effects. Using electrophysiological 
and molecular analyses, we investigated the effect of PER against in vitro ischemia obtained by 
oxygen and glucose deprivation (OGD) in rat slices of two brain structures particularly sensitive to 
ischemic insults, the nucleus striatum and the hippocampus. We found that in these regions, while 
PER reduced the excitatory synaptic transmission without altering the electric membrane 
excitability, it was neuroprotective against OGD at doses that did not affect physiological long-term 
potentiation (LTP). Furthermore, in both the analysed regions, PER blocked the pathological form 
of LTP, namely ischemic LTP (iLTP). Finally, we proved that the neuroprotective effect of PER 
against OGD was due to its capability to normalize the subunit synaptic localization and function of 
AMPAR altered after an ischemic insult. Taken together these findings support the idea that PER is 
a drug potentially effective to counteract in vivo ischemic damage. 
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Introduction 
Energy depletion, caused by reduced blood flow to the central nervous system (CNS), is responsible 
for diminished supplement of oxygen, glucose and other substances to neurons leading to persistent 
neuronal depolarization accompanied by increased glutamate release in the extracellular space 
(Dirnagl et al., 1999).  
The subsequent activation of synaptic and non-synaptic glutamate receptors has been suggested to 
initiate excitotoxic cascades representing a major key pathogenic event in ischemic neuronal death 
(Bano and Nicotera, 2007; Kwak and Weiss, 2006; Lai et al., 2014; Lipton, 1999). 
N-methyl-d aspartic receptors (NMDARs) and -amino-3-hydroxy-5methyl-4-isoxazole propionate 
receptors (AMPARs) seem to be strongly implicated in the ischemic-related excitotoxic pathway. In 
fact, many studies reported that after an ischemic insult these receptors display altered expression 
and function (Arundine and Tymianski, 2004; Lea and Faden, 2001). The ischemic insult leads to 
increased GluA1/GluA2 AMPAR subunit ratio, which allows massive Ca
2+
 entry through the 
receptor (Pellegrini-Giampietro et al., 1997). The AMPAR has also a crucial role in the induction 
and maintenance of the long-term potentiation (LTP) and long-term depression (LTD), two forms of 
synaptic plasticity that are thought to represent the basis of memory and learning processes 
(Buonarati et al., 2019; Malinow and Malenka, 2002). LTP requires changes in the number and 
function of glutamate receptors, including the synthesis and the insertion in the postsynaptic 
membrane of new AMPARs to ease the potentiation of synaptic transmission (Buonarati et al., 
2019). The relation occurring among ischemic insult, change of glutamate neurotransmission and 
synaptic plasticity is suggested by the evidence that a brief oxygen and glucose deprivation (OGD) 
is able to induce a pathological form of synaptic plasticity named ischemic long-term potentiation 
(iLTP) (Calabresi et al., 2002). This aberrant form of synaptic plasticity has been considered the 
electrophysiological correlate of the molecular alterations taking place during apoptotic cell death, 
with still unknown functional consequences (Calabresi et al., 2003). Thus, during pathological 
conditions characterized by limited neuronal energetic supply, the consequent altered neuronal 
synaptic plastic properties could negatively impair the cognitive abilities (Delcasso et al., 2014) and 
brain coping strategies of patients. A hypothetical optimal neuroprotective strategy for brain 
ischemia treatment should counteract the activation of the glutamate-triggered excitotoxic pathways 
without impairing the capability of neurons to express physiological synaptic plasticity. Several 
glutamate receptors antagonists have been tested as neuroprotective compounds against brain 
ischemia (Hanada et al., 2011). AMPARs antagonist such as Talampanel and other non-competitive 
AMPA antagonists have also been considered since these drugs are able to attenuate brain damage 
after focal or cerebral ischemia (Meldrum and Rogawski, 2007). However, the use of AMPAR 
antagonists for clinical use also present important limitations since they exhibit many short-
comings, such as poor solubility, a short half-life, and precipitation in the kidney (Hanada et al., 
2011). 
Perampanel (PER) is a AMPARs antagonist, unique for its capability to cross the blood brain 
barrier respect to other AMPAR antagonists, for showing a good oral bioavailability and favourable 
pharmacokinetic properties (Rogawski and Hanada, 2013). Thus, due to these properties and the 
mechanism of action antagonizing glutamate transmission, it is possible to hypothesize a beneficial 
neuroprotective effect of PER against energetic failure that will preserve neuronal transmission. 
Following this hypothesis, we analysed the potential neuroprotective effect of PER in the nucleus 
striatum and in the hippocampus, two brain structures particularly vulnerable to ischemic insults 
and of pivotal importance for different forms of learning and memory. Furthermore, we tested 
whether the doses of PER exerting neuroprotective effects against OGD were able to influence the 
expression of synaptic plasticity as well as the postsynaptic localization of AMPA receptor subunits 
in both analysed regions.  
 
Materials and methods 
All experiments were conducted in conformity with the European Communities Council Directive 
of November 1986 (86/609/ECC), in accordance with a protocol approved by the Animal Care and 
Use Committee at the University of Perugia and with the ARRIVE guidelines. All efforts were 
made to minimize the number of animals used and their suffering. 
 
Electrophysiology 
Corticostriatal and hippocampal slices (thickness 270 and 400 µm respectively) were cut from 
brains of four weeks old Wistar male rats (Charles River, Italy) using a vibratome. All slices were 
submerged in an artificial cerebrospinal fluid (ACFS) or Kreb's solution, bubbled with 95% O2, 5% 
CO2 gas mixture at 32°C for cortical striatal slices and 29°C for hippocampal slices (flow rate 2.9-
3.3 ml/min). The composition of the Kreb's solution was (in mmol/L) 126 NaCl, 2.5 KCl, 1.2 
MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 10 Glucose and 25 NaHCO3. Each single striatal and hippocampal 
slice was transferred to a recording chamber and submerged in a continuously flowing Kreb's 
solution for both extracellular and patch-clamp recordings. For extracellular recordings an 
Axoclamp 2B amplifier (Molecular Devices, USA) was used. 
Hippocampal extracellular excitatory post-synaptic potentials (fEPSPs) were evoked with a 
stimulating bipolar electrode placed in the Schaffer collateral fibers (10ms duration; 30-50 V 
intensity) and recorded with a glass microelectrode filled with 2 mol/L NaCl placed in the stratum 
radiatum of the CA1 hippocampal region. Striatal fEPSPs were evoked every 10 s by stimulating 
the cortical glutamatergic afferents to the dorsolateral striatum.  
In vitro ischemia was delivered by switching the standard Kreb's solution to an artificial 
cerebrospinal fluid solution gassed with 95% N2 and 5% CO2 (oxygen and glucose deprivation, 
OGD) in which sucrose replaces glucose. The duration of OGD protocol was region specific, 10 
min for the striatum and 8 min for the CA1 hippocampal region (Mazzocchetti et al., 2018).  
To induce LTP in the CA1 hippocampal region, a high-frequency stimulation (HFS) protocol 
consisting of one train lasting 1 s, was delivered at 100 Hz (Kleschevnikov et al., 2004) after 
acquiring a stable baseline for 10 minutes. In hippocampal slices, iLTP was induced by a brief OGD 
episode (2-2.5 minutes) (Crepel et al., 1993). In these experiments, fEPSPs were evoked in presence 
of a Kreb’s solution containing 10 µM bicuculline to block GABAA receptors, 0.3 mM Mg
2+
 to 
enhance NMDA receptor-mediated response and 10 µM glycine to saturate the glycine allosteric 
site of the NMDA receptors (Crepel and Ben-Ari, 1996; Crepel et al., 1993). 
Whole-cell voltage-clamp recordings (access resistance 15-30MΩ; holding potential -80 mV/-
60mV) were performed on striatal spiny projection neurons (SPNs) and pyramidal cells visualized 
using differential interference contrast (Nomarski) and infrared microscopy (Olympus). Recordings 
were made with a Multiclamp 700B amplifier (Molecular Devices), using a borosilicate glass 
pipette (4-7MΩ) filled with a standard internal solution contained (in mM): 145 K+-gluconate, 0.1 
CaCl2, 2 MgCl2, 0.1 EGTA, 10 HEPES, 0.3 Na
+
-GTP and 2 Mg
2+
-ATP, adjusted to pH 7.3 with 
KOH.  
In order to evoked postsynaptic excitatory currents (EPSCs) from SPNs and pyramidal cell a bipolar 
stimulating electrode were placed intrastriatal or on Schaffer collateral fibers, respectively. Current-
voltage (I-V) relationship of both CA1 pyramidal cells and in SPNs was obtained by applying 
hyperpolarizing and depolarizing steps of current (50 pA, 2 sec). All the experiments were 
conducted in the presence of 50µM of GABA receptor antagonist picrotoxin, in order to isolate the 
glutamate transmission.  
In the striatum, LTP was induced by HFS protocol consisting of three trains lasting 3 s (20 s 
interval) delivered at 100 Hz. During HFS protocol, the stimulus intensity was increased to supra-
threshold levels. External Mg
2+
 ions were omitted to maximize the contribution of NMDA receptors 
during LTP experiments (Calabresi et al., 1992).  
The iLTP was induced in corticostriatal slices by a brief OGD episode (2-2.5 minutes). Also in this 
case, external Mg
2+
 ions were omitted to maximize the contribution of NMDA receptors during 
LTP experiments (Calabresi et al., 1992) and the SPNs were clamped to a holding potential of -50 
mV.  
 
 
Subcellular fractionation and western blotting  
For the purification of triton-insoluble postsynaptic fractions (TIF), striatal and hippocampal were 
homogenized with a Teflon-glass potter in ice-cold buffer containing (in mM) 320 sucrose, 1 
Hepes, 1 MgCl2, 1 NaHCO3, 0.1 phenylmethylsulfonylfluoride at pH 7.4 in the presence of 
Complete
TM
 Protease Inhibitor Cocktail Tablets (Roche Diagnostics, Basel, Switzerland) and 
phosSTOP
TM
 Phosphatase Inhibitor (Roche Diagnostics). The sample was spun at 13.000 g x 15 
minutes at 4°C. The resulting pellet was resuspended in Triton-KCl buffer (0.5% Triton X-100 and 
150 mM KCl) and, after 15 minutes incubation on ice, it was spun further at 100.000 g x 1 hour at 
4°C. The pellet (triton-insoluble postsynaptic fraction, TIF) was resuspended in 20 mM Hepes 
buffer supplemented with Complete
TM
 Protease Inhibitor Cocktail Tablets and stored at -80°C.  
The levels of AMPAR subunits in the homogenate and TIF were analysed by western blotting. 
Homogenate and TIF samples were separated onto a 7% acrylamide/bis acrylamide gel. Proteins 
were blotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and probed with the 
appropriate primary antibodies followed by the corresponding HRP-conjugated secondary 
antibodies. Labeling detection was performed with ChemiDoc MP Imaging System (Bio-Rad) and 
images were acquired with ImageLab software (Bio-Rad). The primary antibodies used in this study 
are anti-GluA1 (dilution 1:1000; Neuromab), anti-GluA2 (dilution 1:500; Neuromab), anti-GluA3 
(dilution 1:1000; Synaptic System), anti-GluA1p845 (dilution 1:1000; Merck Millipore) and anti-
tubulin (dilution 1:20000; Sigma-Aldrich). The latter was always used as loading control for 
normalization.  
Drugs 
Drugs were bath applied by dissolving them to the desired final concentration in the Krebs’ solution 
and by switching the perfusion from control solution to drug-containing solution. PER was kindly 
provided by EISAI. In order to evaluate the effect of PER on I-V relationship and synaptic 
transmission, PER was applied in the recording chamber for at least 20 minutes. In OGD 
experiments PER was delivered on the recording chamber for at least 10 minutes before OGD and 
maintained throughout the experiment. During the HFS protocol, PER was maintained throughout 
all the duration of the recording.  
 
Statistical analysis 
For electrophysiological experiments data analysis was performed off-line using Clampfit 10 
(Molecular Devices). Values given in the text and figures are mean ± SEM, n representing the 
number experiments. Changes of the fEPSP amplitude and slope are expressed as percentage of the 
baseline, the latter representing the normalized fEPSP or EPSC mean amplitude acquired during a 
stable period (10-15 minutes) before the start of the experimental protocols involving PER, OGD 
and HFS. Two-way ANOVA or the Student's t-test was used. For the molecular analysis data were 
normalized against tubulin and shown in the graph as mean ± SEM. The one-way ANOVA or the 
Student's t-test was used.  
The significance level was established at *p < 0.05, **p<0.01, ***p<0.001. 
 
Results 
Effect of PER on synaptic transmission 
We tested the effects of PER on the excitatory synaptic transmission by extracellular field potentials 
recordings of the CA1 hippocampal region and dorsal striatum stimulating respectively the 
Schaffer’s collaterals or the corticostriatal glutamatergic fibers. After acquiring stable fEPSPs 
responses for 10 minutes, PER was bath applied for 20 minutes on the slice at different 
concentrations (striatum 0.1 nM to 1000 nM, hippocampus 1 nM to 3000 nM, Fig. 1A, B). As 
expected, PER dose-dependently reduced the fEPSP response in both striatum and hippocampus. 
Specifically, we found that in striatal slices, while 0.1-0.3 nM PER did not reduce the fEPSP 
amplitude, doses higher than 1 nM were effective, (PER 3 nM, fEPSP amplitude 87.51 ± 2.27%, 
control vs 1 nM PER (n=12) Student’s t-test, p<0.01, Fig. 1A). The calculated IC50 for the dose-
response relationship was 132 nM.  
In the hippocampus PER doses lower than 100 nM were unable to reduce the fEPSP slope. In fact, 
while 1-30 nM PER did not affect the response, in the presence of 100 nM PER the fEPSP slope 
was 80.49 ± 3.10 % of the baseline (control vs PER, (n=5) Student’s t-test, p<0.05, Fig. 1B). In the 
CA1 hippocampal region, PER induced a dose-dependent reduction of the fEPSP slope with an IC50 
of 355 nM (Fig. 1B). 
 
Effect of PER on the OGD-induced loss of the field potential  
We then analysed the possible neuroprotective effect of PER against neuronal damage induced by 
in vitro ischemia (OGD) in the nucleus striatum. After recording in striatal slices a stable fEPSP for 
10 minutes, an oxygen and glucose-free solution was applied for 10 minutes, a time known to 
produce the irreversible loss of the fEPSP amplitude in this region (Calabresi et al., 2000). The 
fEPSP amplitude was recorded for additional 30 minutes both in control experiments or in the 
presence of different concentrations of PER. We found that, the ischemic insult irreversibly 
suppressed the fEPSP both in control conditions and in the presence of 0.1 nM PER (control (n=7) 
vs PER (n=6), two-way ANOVA, p>0.05; Fig. 2A). Conversely, 0.3 nM and 1 nM PER were able 
to induce a significant recovery of the fEPSP amplitude, as measured 30 minutes following OGD 
(PER 0.3 nM fEPSP amplitude 78.72 ± 8.17% of baseline, control (n=7) vs PER (n=7), two-way 
ANOVA, p<0.001; PER 1 nM fEPSP amplitude 85.44 ± 11.55% of baseline, control (n=7) vs PER 
(n=6), two-way ANOVA, p<0.001; Fig. 2B, C). These data indicate that, in the nucleus striatum, 
the neuroprotective effect of PER against in vitro ischemia is dose-dependent presenting a maximal 
neuroprotective effect achieved by 1 nM of the drug and a calculated EC50 of 0.16 nM (Fig. 2D). In 
order to test whether the first dose of PER that was able to protect neurons against in vitro ischemia 
could affect the membrane excitability of SPNs, we performed whole-cell patch-clamp recordings 
of striatal SPNs to measure the firing activity before and 10 minutes after exposure of the slices to 
0.3 nM (Fig. 2E). The calculated I-V curves showed no differences between the recordings obtained 
in control conditions and in the presence of 0.3 nM PER for the striatum (striatum, control vs 0.3 
nM PER (n=5), two-way ANOVA, p>0.05). 
Since the CA1 hippocampal region is one of the most vulnerable areas of the brain to ischemia 
(Pulsinelli, 1985), 8 minutes OGD are sufficient to produce the irreversible depression of synaptic 
activity. We found that, in the hippocampal CA1 region, the ischemic insult irreversibly suppressed 
the fEPSP both in control experiments and in the presence of 10 nM PER (control (n=7) vs PER 
(n=5), two-way ANOVA, p>0.05, Fig. 3A). Conversely, 30 and 100 nM PER significantly 
recovered the fEPSP, as measured 30 minutes after the OGD application (PER 30 nM, fEPSP slope 
53.53 ± 9.63% of baseline, control (n=7) vs PER (n=6), two-way ANOVA, p<0.001, Fig. 3B; PER 
100 nM, fEPSP slope 98.87 ± 5.69% of baseline control (n=7) vs PER (n=5), two-way ANOVA, 
p<0.001, Fig. 3C). Interestingly, 100 nM PER caused only a mild reduction of excitatory synaptic 
transmission (Fig. 1B). The neuroprotective effect of PER was dose-dependent with a calculated 
EC50 of 30.04 nM (Fig. 3D). The calculated I-V curves showed no differences between the 
recordings obtained in control conditions and in the presence of 30 nM PER of hippocampal CA1 
pyramidal neurons (control vs 30 nM PER (n=4), two-way ANOVA, p>0.05; Fig. 3E). 
 
Effect of PER on physiological and ischemic long-term potentiation of synaptic transmission 
AEDs are known to possibly induce memory deficits in patients, even at therapeutic doses, as 
confirmed also in experimental models (Detrait et al., 2010). Thus, we tested whether PER 
neuroprotective doses against OGD impaired LTP induction both in the nucleus striatum and 
hippocampus. To achieve this goal, we recorded striatal EPSCs for SPNs and fEPSPs for pyramidal 
cells, for 10 minutes and induced LTP by HFS of afferent fibres to the striatum or to the CA1 
hippocampal region. The EPSCs amplitude measured 30 minutes after the HFS protocol in the 
striatum and the fEPSP slopes measured 50 minutes after the HFS in the hippocampus were not 
significantly different in control experiments and in the presence of PER in both the structures 
(striatum, EPSCs amplitude in control conditions 158.48 ± 6.16%, in PER 0.3 nM 144.10 ± 
11.31%, control (n=5) vs PER (n=5), two-way ANOVA, p>0.05; Fig. 4A; hippocampus, fEPSP 
slope in control conditions, 167.76 ± 16.56%, in 30 nM PER, 139.92 ± 9.28%, control (n=5) vs 
PER (n=5), two-way ANOVA, p>0.05, Fig. 4B). It should be noted that in the CA1 hippocampal 
region 100 nM PER, the dose producing maximal neuroprotective effect, significantly impaired the 
LTP (data not shown). 
We next tested the effects of PER on iLTP, an aberrant form of synaptic plasticity reflecting 
metabolic neuronal suffering induced by an ischemic insult. In the nucleus striatum, a brief OGD 
episode (2-2.5 minutes) is able to induce a transient depression of the EPSCs of SPNs followed, 
after washout of the ischemic solution, by reversal of the phenomenon and a subsequent and 
persistent potentiation of the EPSCs amplitude (EPSCs amplitude 30 minutes after OGD 155.15 ± 
4.28% of baseline; Fig. 4 C). We found that the application of 0.3 nM PER prevented the 
occurrence of iLTP (EPSCs amplitude 85.77 ± 7.78%, control (n=4) vs PER (n= 4), p<0.001, Fig. 
4C). As previously shown (Costa et al., 2011), in the hippocampus OGD was also able to induce 
iLTP (fEPSPs slope 30 minutes after OGD 140.91 ± 1.90% of baseline) and interestingly, 30 nM 
PER was able to prevent the induction of the pathological LTP in this region (PER, fEPSPs slope 
30 minutes after OGD 98.37 ± 6.82% of baseline; control (n=6), vs PER 30 nM (n=5), p<0.001, 
Fig. 4D). 
 
Effect of PER on OGD-induced alterations of AMPA receptor subunit composition 
We evaluated by western blotting analysis in a total homogenate fraction and in a triton-insoluble 
post-synaptic fraction (TIF), the possibility that alterations in the levels and subunit composition of 
AMPA may be involved in the observed effects induced by OGD and treatment with PER. Analysis 
of AMPAR subunit levels in total homogenate indicated a higher expression both GluA1 and 
GluA2 subunits in the hippocampus compared to the striatum (p<0.01, GluA1, hippocampus vs 
striatum; p<0.05, GluA2, hippocampus vs striatum; Fig. 5A).  
Moreover, we found that application of the OGD protocol to hippocampal slices induced a 
significant increase of GluA1 AMPAR subunit synaptic levels (*p<0.05, post-OGD vs pre-OGD, 
Fig. 5B). Notably, concomitant treatment with PER was sufficient to rescue synaptic GluA1 subunit 
to control levels (#p<0.05, post-OGD + PER vs post-OGD, Fig. 5B). Similarly, PER significantly 
decreased GluA1 synaptic levels in the striatum from OGD-treated corticostriatal slices (#p<0.05, 
post-OGD + PER vs post-OGD, Fig. 5C). No effect on GluA2 and GluA3 subunit levels at synapses 
was observed after OGD in absence or presence of PER both in hippocampus (Fig. 5B) and in 
striatum (Fig. 5C). Finally, no alteration of the phosphorylation of GluA1-Ser845, a well-validated 
marker of synaptic plasticity (Esteban et al., 2003; Hu et al., 2007; Oh et al., 2006), was found both 
in hippocampus (Fig. 5B) and in striatum (Fig. 5C). 
 
Discussion 
In this study we explored the possible neuroprotective effect of the AMPAR antagonist PER on 
energy deprivation induced by bath application of an oxygen- and glucose-free solution (OGD) on 
rat hippocampal and striatal slices. We found that PER, at doses unable to affect neurotransmission 
and the physiological LTP, was able to reduce the detrimental effects of OGD on hippocampal and 
striatal neurons, including the expression of iLTP, a pathological form of synaptic plasticity. 
Finally, we proved that PER exerted this neuroprotective effect through the reduction of GluA1-
bearing AMPARs that was increased during OGD.  
We found that in the nucleus striatum and in the hippocampus the AMPARs antagonist PER at 
higher concentrations (higher than 30 nM in the striatum, higher 100 nM in the hippocampus) 
reduces synaptic transmission in a concentration-dependent manner, as previously described 
(Ceolin et al., 2012). We found that the IC50 of PER in the striatum (132 nM) was significantly 
lower than that measured in the hippocampus (355 nM), highlighting the higher sensitivity of the 
striatum to the drug in respect to the hippocampus. This difference could be explained by the 
different expression of AMPARs in these brain regions, as observed by molecular analysis of 
AMPARs subunit levels in total homogenate of these tissues.  
Moreover, we found that PER exerted, a dose-dependent, neuroprotective effect also against in vitro 
ischemia obtained by OGD, and it was able to block the pathological iLTP in both the striatum and 
hippocampus. In fact, AMPARs are known to be particularly important for striatal (Di Filippo et al., 
2008; Saulle et al., 2002) and hippocampal iLTP (Dias et al., 2013). 
It is worth noting that the neuroprotective effect of PER was achieved at very low concentrations, 
respect to that required for antiepileptic action (Biton, 2007; Costa et al., 2011). Similarly, the 
antiepileptic drug (AED) Zonisamide had also neuroprotective effects against iLTP at doses lower 
than that used as anticonvulsant (Costa et al., 2011).  
A possible explanation of this neuroprotective effect could rely on the changes of AMPARs subunit 
composition induced by ischemic insult (Dos-Anjos et al., 2009), influencing the synaptic 
susceptibility to PER. In fact, we found that OGD selectively increased the number of AMPARs 
expressing the GluA1 subunit, which possibly leads to the presence at synapses of novel GluA2-
lacking Ca
2+
 AMPARs. PER seems to act specifically on GluA1 subunit thus it might be possible 
that it is able to protect neurons at doses lower than that affecting synaptic transmission, due to the 
high expression of GluA1 subunit after OGD in contrast to physiological conditions, in which the 
high majority of AMPARs express a GluA1/GluA2 or GluA2/GluA3 configuration. Indeed, PER 
neuroprotective effect might be related to the selective block of GluA1 subunit, rescuing 
physiological Ca
2+
-impermeable AMPARs at synaptic level after an ischemic insult and preventing 
the harmful increase of intracellular Ca
2+ 
leading to neuronal death. Moreover, the observation that 
PER-dependent neuroprotective effects were achieved at doses not significantly influencing basal 
excitatory transmission could also suggest that the PER-dependent beneficial effect acted through 
non-synaptic AMPA receptors or, more intriguingly, additionally unveiled neuroprotective 
pathways.  
Interestingly, in support of the neuroprotective use of PER, it has been demonstrated that this drug 
was able to ameliorate the post-stroke motor function and the spatial working memory in a rat 
model of transient middle cerebral artery occlusion (MCAO) through possible anti-inflammatory 
and antioxidant mechanisms (Nakajima et al., 2018). Moreover, PER has been reported to reduce 
brain oedema, brain infarct volume and neuronal apoptosis following focal cerebral ischemia in rats 
(Niu et al., 2018). Unlike other compounds affecting AMPAR function such as NBQX or 
Talampanel which exhibit many shortcomings (Hanada et al., 2011; Langan et al., 2003), PER 
present good oral bioavailability and favourable pharmacokinetic properties (Rogawski and 
Hanada, 2013) making it a good candidate for post-stroke neuroprotective strategy. 
Although many AEDs, such as PER, present potential neuroprotective effect, they are known to 
exert negative dose-dependent effects on cognitive functions (Helmstaedter and Witt, 2013; Witt et 
al., 2015). In fact, they have been shown to affect cognition in adult human subjects (Sgobio et al., 
2010) and to affect morphogenesis and brain development by influencing synaptogenesis, synaptic 
plasticity and neural network formation (Caccamo et al., 2016; Ikonomidou and Turski, 2010). 
Accordingly, phenytoin can induce brain atrophy in patients after long-term use (Ney et al., 1994), 
while valproic acid may produce morphologic alterations and impairment of specific hippocampal-
dependent memory tasks (Sgobio et al., 2010). For this reason, the evaluation of the effects of 
AEDs on synaptic plasticity and cognition is critical. 
Thus, we evaluated whether PER, at doses able to protect neurons from OGD, also affected the 
physiological expression of LTP in hippocampal and striatal areas. Our results suggest that the dose 
of PER exerting neuroprotective effect against in vitro ischemia does not alter LTP of striatal 
neurons. In CA1 hippocampal region, while 30nM PER is neuroprotective against OGD and LTP is 
spared, the neuroprotective effect of higher PER doses (100 nM) is associated to impaired LTP. 
Thus, it is conceivable that PER has a dose-dependent effect on LTP, reflecting its direct effect on 
synaptic transmission. These preclinical results could justify the clinical data of the literature, where 
Witt and colleagues demonstrated a considerable adverse effect of a higher drug load on cognition, 
especially on executive functions (Witt et al., 2015).  
 
Conclusion 
Our results suggest that PER exerts a neuroprotective effect against energy deprivation in two brain 
regions particularly sensitive to ischemic insult and of fundamental importance in memory 
processes. A significant protection was reached at concentrations of the drug unable to affect 
synaptic transmission and plasticity with different efficacy in striatum and hippocampus. Taken 
together these findings support PER, as a third generation AED, as a good candidate for further 
investigation for the treatment of brain ischemia. 
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Figure Legends 
Figure 1. Effect of PER on physiological synaptic transmission in striatum and CA1 
hippocampal region. A) Upper representative traces of striatal fEPSPs recorded in Kreb’s solution 
or in the presence of increasing doses of PER; the graph describes the dose-response curve for PER 
showing an IC50 of 132 nM (control vs 0.1 nM PER (n=7), p>0.05; control vs 0.3 nM PER (n=11), 
p>0.05, control vs 3 nM PER (n=8), p<0.01; control vs 10 nM PER (n=6), p<0.05, control vs 30 
nM PER (n=9), p<0.01, control vs 300 nM PER (n=6), control vs 1000 nM PER (n=5), p<0.01). B) 
Upper representative traces of hippocampal fEPSPs. The graph describes the dose-response curve 
for PER showing an IC50 of 355 nM (control vs 1 nM to 30 nM, (n=5, for each concentration), 
p>0.05; control vs 300 nM PER (n=5), p<0.01, control vs 3000 nM PER (n=5), p<0.001). 
Figure 2. Neuroprotective effect of PER against OGD in striatum. A-C) Upper representative 
traces of striatal fEPSPs recorded pre and post-OGD both in control condition and in the presence 
of increasing doses of PER. The time-course plot shows the effect of OGD in control slices and in 
slices treated with 0.1, 0.3 and 1 nM PER (control open circle; 0.1 nM PER blue circle; 0.3 nM 
PER (blue square; 1 nM PER blue diamond). D) Dose-response curve of the neuroprotective effect 
of PER on in vitro ischemia induced by the OGD in the striatal region. The EC50 is 0.16 nM. E) 
Input-Output (I/O) curves recorded from striatal neurons show no difference between neurons 
recorded in control condition and those treated with PER (striatum, control open circle vs 0.3 nM 
PER blue circle).  
Figure 3. Neuroprotective effect of PER against OGD in CA1 hippocampal region. A-C) 
Upper representative traces of striatal fEPSPs recorded pre and post-OGD both in control condition 
and in the presence of increasing doses of PER. The time-course plot shows the effect of OGD in 
control slices and in slices treated with 10, 30 and 100 nM PER (control open circle; 10 nM PER 
orange circle; 30 nM PER orange square; 100 nM PER orange diamond). D) Dose-response curve 
of the neuroprotective effect of PER on in vitro ischemia induced by the OGD protocol. The graph 
show that the maximal neuroprotective effect was achieved with 100 nM PER. The EC50 was 34.21 
nM. E) Input-Output (I/O) curves recorded from pyramidal neurons show no difference between 
neurons recorded in control condition and those treated with PER (control open circle vs 30 nM 
PER orange circle). 
Figure 4. Effect of PER on LTP and iLTP in the dorsolateral striatum and in CA1 
hippocampal region. A, C) Representative traces of EPSCs recorded before and after the HFS (A) 
or the OGD protocol (C), in control condition and in the presence of 0.3 nM PER. The time-courses  
show the EPSCs amplitude before and after the HFS (A) or OGD (C) protocol, in control condition 
(open circle) and in the presence of 0.3 nM PER (blue circle). B, D) Representative traces of 
fEPSPs recorded before and after the HFS (B) or the OGD (D) protocol, in control condition and in 
the presence of 30 nM PER (orange circle). Time-course of the fEPSPs amplitude before and after 
the HFS (B) or OGD (D) protocol, in control condition (open circle) and in the presence of 30 nM 
PER (orange circle).  
Figure 5. Levels of AMPA receptor subunits in hippocampus and striatum in physiological 
condition, after OGD insult and in the presence of PER. A) WB analysis for GluA1, GluA2 and 
GluA3 subunits of the AMPARs in the homogenate fraction from striatum and hippocampus. Data 
are normalized against tubulin and are shown in the graph as mean ± SEM. **p<0.01, *p<0.05. B-
C) WB analysis for GluA1, GluA1-p845, GluA2 and GluA3 subunits of the AMPARs in the triton 
insoluble postsynaptic fraction (TIF) from control and OGD-treated corticostriatal and hippocampal 
slices in absence or presence of PER. Data are normalized against tubulin and are shown in the 
graph as mean ± SEM. *p<0.05. 
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